<DOC>
	<DOCNO>NCT01034709</DOCNO>
	<brief_summary>Subjects symptomatic CMV infection , enrol clinical study , monitor antiviral therapy .</brief_summary>
	<brief_title>Evaluation Artus® CMV PCR Test</brief_title>
	<detailed_description>The human Cytomegalovirus ( CMV ) find blood , tissue nearly secretory fluid infect person . Transmission oral , sexual , via blood transfusion , organ transplantation , intrauterine , perinatal . Infection CMV preadolescence frequently lead asymptomatic infection follow lifelong persistence virus body . Infection post adolescence typically lead symptom resemble mononucleosis ( e.g. , fever , fatigue , hepatitis , etc . ) In contrast , CMV infection immune compromise patient life threaten . A major cause virus-associated morbidity mortality solid organ transplantation patient illness cause CMV ( i.e. , CMV syndrome CMV disease ) . The risk progress CMV disease post-transplant strongly correlate serological status donor ( D ) recipient ( R ) ; high risk group R-/D+ . Patients risk CMV disease manage either preemptively ( i.e. , patient treat antiviral agent evidence CMV infection arises ) , prophylactically ( i.e. , patient treat antiviral agent regardless CMV infection status ) . Monitoring CMV viral load transplant patient antiviral therapy provide effective aid management patient CMV disease . The artus® CMV RG PCR test nucleic acid amplification-based assay quantitation CMV DNA use PCR Rotor-Gene™ 6000 Instrument ( also know Rotor-Gene Q ) software version 2.0.2.3 high . In present study artus CMV RG PCR test result evaluate ability safely effectively monitor transplant patient antiviral therapy compare COBAS® AmpliPrep/COBAS® TaqMan® CMV Test</detailed_description>
	<mesh_term>Cytomegalovirus Infections</mesh_term>
	<criteria>1 . Subjects must kidney transplant . 2 . Subjects present hospital , clinic physician office posttransplantation care . 3 . Subjects must 18 year age old . 4 . Subjects provide informed consent . 5 . Subjects must CMV infection demonstrate positive result site 's CMVPCRLaboratory Developed Test ( CMVPCRLDT ) 6 . Subjects must candidate , treat ganciclovir and/or valganciclovir antiviral therapy . 1 . Subjects wherein HIV status positive . 2 . Specimens le 1.0 ml EDTA plasma artus test . 3 . Subjects sample collect , handle and/or store inappropriately and/or determine unsatisfactory processing/testing artus CMV RG PCR test ( explanation provide case subject exclusion ) . EDTA plasma specimen store inappropriately include follow storage condition : whole blood frozen ; whole blood process plasma 24 hour collection ; plasma store room temperature 24 hour 4C 5 day 20C 6 month ; freeze plasma two freeze thaw cycle ; Extracted nucleic acid store inappropriately include follow storage condition : extract DNA store 5 day 20C , long six month 20C ; frozen nucleic acid two freeze/thaw cycle . 4 . Specimens store inappropriately test test use site demonstrate CMV infection . ( A site specific memo provide QIAGEN appropriate specimen storage condition . )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Cytomegalovirus</keyword>
	<keyword>CMV</keyword>
</DOC>